JP2007515423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007515423A5 JP2007515423A5 JP2006545535A JP2006545535A JP2007515423A5 JP 2007515423 A5 JP2007515423 A5 JP 2007515423A5 JP 2006545535 A JP2006545535 A JP 2006545535A JP 2006545535 A JP2006545535 A JP 2006545535A JP 2007515423 A5 JP2007515423 A5 JP 2007515423A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmacologically active
- active derivative
- use according
- dithiol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 8
- LZENMJMJWQSSNJ-UHFFFAOYSA-N 3H-1,2-dithiole-3-thione Chemical compound S=C1C=CSS1 LZENMJMJWQSSNJ-UHFFFAOYSA-N 0.000 claims 6
- 206010061323 Optic neuropathy Diseases 0.000 claims 6
- 208000017442 Retinal disease Diseases 0.000 claims 6
- 206010038923 Retinopathy Diseases 0.000 claims 6
- 229930003935 flavonoid Natural products 0.000 claims 6
- 150000002215 flavonoids Chemical class 0.000 claims 6
- 235000017173 flavonoids Nutrition 0.000 claims 6
- 150000002540 isothiocyanates Chemical class 0.000 claims 6
- 208000020911 optic nerve disease Diseases 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims 4
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims 4
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 claims 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims 2
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- 239000004258 Ethoxyquin Substances 0.000 claims 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims 2
- 238000006845 Michael addition reaction Methods 0.000 claims 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims 2
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 claims 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 claims 2
- 235000019285 ethoxyquin Nutrition 0.000 claims 2
- 229940093500 ethoxyquin Drugs 0.000 claims 2
- 238000002513 implantation Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims 2
- 230000005937 nuclear translocation Effects 0.000 claims 2
- CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 claims 2
- 229950008687 oltipraz Drugs 0.000 claims 2
- 229960001285 quercetin Drugs 0.000 claims 2
- 235000005875 quercetin Nutrition 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 229960005559 sulforaphane Drugs 0.000 claims 2
- 235000015487 sulforaphane Nutrition 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53177003P | 2003-12-22 | 2003-12-22 | |
| US60/531,770 | 2003-12-22 | ||
| PCT/US2004/042687 WO2005063295A1 (en) | 2003-12-22 | 2004-12-17 | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010247809A Division JP2011046736A (ja) | 2003-12-22 | 2010-11-04 | 緑内障性網膜症および視神経障害の処置のための薬剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007515423A JP2007515423A (ja) | 2007-06-14 |
| JP2007515423A5 true JP2007515423A5 (enExample) | 2007-10-11 |
| JP4755599B2 JP4755599B2 (ja) | 2011-08-24 |
Family
ID=34738696
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006545535A Expired - Fee Related JP4755599B2 (ja) | 2003-12-22 | 2004-12-17 | 緑内障性網膜症および視神経障害の処置のための薬剤 |
| JP2010247809A Withdrawn JP2011046736A (ja) | 2003-12-22 | 2010-11-04 | 緑内障性網膜症および視神経障害の処置のための薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010247809A Withdrawn JP2011046736A (ja) | 2003-12-22 | 2010-11-04 | 緑内障性網膜症および視神経障害の処置のための薬剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050137146A1 (enExample) |
| EP (2) | EP1803468B1 (enExample) |
| JP (2) | JP4755599B2 (enExample) |
| KR (1) | KR20060127043A (enExample) |
| CN (1) | CN1897972A (enExample) |
| AT (2) | ATE357932T1 (enExample) |
| AU (1) | AU2004308919B2 (enExample) |
| BR (1) | BRPI0417987A (enExample) |
| CA (1) | CA2547852A1 (enExample) |
| CY (2) | CY1106623T1 (enExample) |
| DE (1) | DE602004005617T2 (enExample) |
| DK (2) | DK1803468T3 (enExample) |
| ES (2) | ES2282926T3 (enExample) |
| MX (1) | MXPA06006980A (enExample) |
| PL (2) | PL1803468T3 (enExample) |
| PT (2) | PT1803468E (enExample) |
| SI (2) | SI1696958T1 (enExample) |
| WO (1) | WO2005063295A1 (enExample) |
| ZA (1) | ZA200604862B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6881198B2 (en) * | 2001-01-09 | 2005-04-19 | J. David Brown | Glaucoma treatment device and method |
| ZA200604862B (en) * | 2003-12-22 | 2007-10-31 | Alcon Inc | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| WO2005102345A1 (en) * | 2004-03-30 | 2005-11-03 | Alcon, Inc. | Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
| WO2006030907A1 (ja) * | 2004-09-16 | 2006-03-23 | Redox Bioscience Inc. | 網膜保護剤 |
| CA2621993A1 (en) * | 2005-09-16 | 2007-03-29 | Bg Implant, Inc. | Glaucoma treatment devices and methods |
| WO2008016095A1 (en) * | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| JP2010505958A (ja) * | 2006-10-10 | 2010-02-25 | バーンハム インスティトゥート フォー メディカル リサーチ | 神経防護作用組成物および方法 |
| JP2008247898A (ja) * | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| HUE033288T2 (en) | 2008-04-18 | 2017-11-28 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives |
| KR101735807B1 (ko) | 2008-04-18 | 2017-05-15 | 리타 파마슈티컬스 잉크. | Ｃ-17에 아미노 및 기타 변형을 갖는 올레아놀산 유도체를 포함하는 항산화 염증 조절제 |
| CA2721665C (en) | 2008-04-18 | 2017-01-24 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| MY163031A (en) | 2010-04-12 | 2017-07-31 | Reata Pharmaceuticals Inc | Method of treating obesity using antioxidant inflammation modulators |
| RU2472475C2 (ru) * | 2010-04-20 | 2013-01-20 | Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) | Способ комбинированного лечения глаукомной оптической нейропатии |
| WO2012009171A2 (en) * | 2010-07-15 | 2012-01-19 | The Schepens Eye Research Institute, Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| RU2447864C1 (ru) * | 2010-09-15 | 2012-04-20 | Инна Витальевна Щербинина | Способ лечения заболеваний зрительного нерва и сетчатки |
| WO2012177831A2 (en) * | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Compounds for treating peripheral neuropathies and other neurodegenerative disorders |
| RU2546019C2 (ru) * | 2013-03-02 | 2015-04-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ лечения глаукомной оптической нейропатии |
| EP2991621B1 (en) * | 2013-05-02 | 2020-12-09 | Retina Foundation of the Southwest | Two-layer ocular implant |
| US10736778B2 (en) | 2014-12-31 | 2020-08-11 | Microoptx Inc. | Glaucoma treatment devices and methods |
| AU2016331925B2 (en) | 2015-09-30 | 2021-04-22 | Microoptx Inc. | Dry eye treatment devices and methods |
| CA3036630A1 (en) | 2016-09-12 | 2018-03-15 | St Ip Holding Ag | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
| JP2019531344A (ja) | 2016-09-12 | 2019-10-31 | エスティー アイピー ホールディング エージー | ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法 |
| MA46749A (fr) | 2016-11-08 | 2019-09-18 | Reata Pharmaceuticals Inc | Méthodes de traitement du syndrome d'alport à l'aide d'un méthyle de bardoxolone ou d'analogues de ce dernier |
| RU2647324C1 (ru) * | 2017-04-24 | 2018-03-15 | Игорь Евгеньевич Хаценко | Способ определения показаний для лечения амблиопии с помощью нейропептидного препарата |
| JP2023528139A (ja) * | 2020-03-30 | 2023-07-04 | ウーハン ニューロフス バイオテクノロジー リミテッド カンパニー | ヒト核因子ｅ２関連因子２の発現ベクター及び発現ベクターの適用 |
| US11135220B1 (en) | 2020-04-08 | 2021-10-05 | St Ip Holding Ag | Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456757A (en) * | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
| US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
| US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| AU689036B2 (en) * | 1995-05-10 | 1998-03-19 | Kureha Chemical Industry Co., Ltd. | Pharmaceutical composition containing substance inhibiting HSP47 production |
| JP3193301B2 (ja) * | 1995-09-14 | 2001-07-30 | 麒麟麦酒株式会社 | 生理活性タンパク質ｐ１６０ |
| US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
| US5681854A (en) * | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
| US6271224B1 (en) * | 1995-12-21 | 2001-08-07 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
| WO1997028130A1 (en) * | 1996-02-02 | 1997-08-07 | Nippon Shinyaku Co., Ltd. | Isoquinoline derivatives and drugs |
| US6586425B2 (en) * | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| JP3872834B2 (ja) * | 1996-03-04 | 2007-01-24 | 第一製薬株式会社 | メイラード反応抑制剤 |
| ES2286834T5 (es) * | 1996-08-12 | 2011-01-31 | Mitsubishi Tanabe Pharma Corporation | Medicamentos que comprenden un inhibidor de la rho quinasa. |
| US5759787A (en) * | 1996-08-26 | 1998-06-02 | Tularik Inc. | Kinase assay |
| JP2002501482A (ja) * | 1997-01-16 | 2002-01-15 | ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド | 抗酸化剤との相乗的相互作用を通じて多環式フェノール化合物の細胞保護効果を強化するための組成物 |
| US6573044B1 (en) * | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
| US6441033B1 (en) * | 1997-12-22 | 2002-08-27 | Alcon Manufacturing, Ltd. | 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists |
| US6274338B1 (en) * | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| WO1999043315A1 (en) * | 1998-02-25 | 1999-09-02 | Shionogi & Co., Ltd. | Therapeutic agent for complication of diabetes |
| US20010041174A1 (en) * | 1998-11-24 | 2001-11-15 | Najam Sharif | Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases |
| US6020383A (en) * | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
| US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
| US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
| WO2002002190A2 (en) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
| GB0030727D0 (en) * | 2000-12-15 | 2001-01-31 | Lumitech Uk Ltd | Methods and kits for detecting kinase activity |
| US6756063B2 (en) * | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
| CA2357265C (en) * | 2001-04-24 | 2004-04-13 | University Of British Columbia | Improved additive for livestock feeds |
| US6884816B2 (en) * | 2001-08-31 | 2005-04-26 | Alcon, Inc. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
| TWI335221B (en) * | 2001-09-27 | 2011-01-01 | Alcon Inc | Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| US7199122B2 (en) * | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
| ATE445405T1 (de) * | 2001-12-18 | 2009-10-15 | Brassica Foundation For Chemop | Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen |
| JP2005526719A (ja) * | 2002-02-15 | 2005-09-08 | ディーエスエム アイピー アセッツ ビー．ブイ． | 血管新生関連病状の治療および予防のための、リコペンを含む組成物 |
| US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
| AU2003263988A1 (en) * | 2002-08-05 | 2004-02-23 | Wackvom, Ltd. | Methods and compositions to treat conditions associated with neovascularization |
| US6747025B1 (en) * | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
| TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| MXPA06006862A (es) * | 2003-12-22 | 2007-01-26 | Alcon Inc | Agentes para el tratamiento de la retinopatia diabetica y formacion de drusen en degeneracion macular. |
| ZA200604862B (en) * | 2003-12-22 | 2007-10-31 | Alcon Inc | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
-
2004
- 2004-12-17 ZA ZA200604862A patent/ZA200604862B/en unknown
- 2004-12-17 JP JP2006545535A patent/JP4755599B2/ja not_active Expired - Fee Related
- 2004-12-17 BR BRPI0417987-0A patent/BRPI0417987A/pt not_active IP Right Cessation
- 2004-12-17 DK DK07105047.0T patent/DK1803468T3/da active
- 2004-12-17 CN CNA2004800384580A patent/CN1897972A/zh active Pending
- 2004-12-17 DE DE602004005617T patent/DE602004005617T2/de not_active Expired - Lifetime
- 2004-12-17 WO PCT/US2004/042687 patent/WO2005063295A1/en not_active Ceased
- 2004-12-17 PL PL07105047T patent/PL1803468T3/pl unknown
- 2004-12-17 KR KR1020067014097A patent/KR20060127043A/ko not_active Ceased
- 2004-12-17 US US11/015,888 patent/US20050137146A1/en not_active Abandoned
- 2004-12-17 AT AT04814825T patent/ATE357932T1/de active
- 2004-12-17 CA CA002547852A patent/CA2547852A1/en not_active Abandoned
- 2004-12-17 AU AU2004308919A patent/AU2004308919B2/en not_active Ceased
- 2004-12-17 SI SI200430296T patent/SI1696958T1/sl unknown
- 2004-12-17 PT PT07105047T patent/PT1803468E/pt unknown
- 2004-12-17 ES ES04814825T patent/ES2282926T3/es not_active Expired - Lifetime
- 2004-12-17 EP EP07105047A patent/EP1803468B1/en not_active Expired - Lifetime
- 2004-12-17 EP EP04814825A patent/EP1696958B1/en not_active Expired - Lifetime
- 2004-12-17 MX MXPA06006980A patent/MXPA06006980A/es active IP Right Grant
- 2004-12-17 AT AT07105047T patent/ATE523208T1/de active
- 2004-12-17 DK DK04814825T patent/DK1696958T3/da active
- 2004-12-17 SI SI200431767T patent/SI1803468T1/sl unknown
- 2004-12-17 PT PT04814825T patent/PT1696958E/pt unknown
- 2004-12-17 PL PL04814825T patent/PL1696958T3/pl unknown
- 2004-12-17 ES ES07105047T patent/ES2371364T3/es not_active Expired - Lifetime
-
2007
- 2007-05-25 CY CY20071100711T patent/CY1106623T1/el unknown
-
2010
- 2010-11-04 JP JP2010247809A patent/JP2011046736A/ja not_active Withdrawn
-
2011
- 2011-02-22 US US13/031,742 patent/US20110144127A1/en not_active Abandoned
- 2011-11-24 CY CY20111101143T patent/CY1112393T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007515423A5 (enExample) | ||
| BRPI0517891A (pt) | composições compreendendo azelastina e métodos de uso das mesmas | |
| US20180105498A1 (en) | Compositions and methods for treating metabolic disorders | |
| PE20040121A1 (es) | Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| NO20080827L (no) | Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon | |
| EP3197437A1 (en) | Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia | |
| JP2011046736A (ja) | 緑内障性網膜症および視神経障害の処置のための薬剤 | |
| Chen et al. | Transdermal rotigotine: A clinically innovative dopamine‐receptor agonist for the management of Parkinson's disease | |
| BRPI0518266A8 (pt) | Medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular | |
| JP2015519329A5 (enExample) | ||
| NO20065878L (no) | Terapeutiske forbindelser | |
| RU2012101792A (ru) | Композиции и способы для лечения бокового амиотрофического склероза | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| CA2453263A1 (en) | Pharmaceutical compositions containing terbinafine and use thereof | |
| ES2236551T3 (es) | Combinacion de principios activos para el tratamiento medico de toxicomanias. | |
| TW202120100A (zh) | 包含檸檬苦素類化合物和dpp-4抑制劑的組合產品 | |
| JP2007515422A5 (enExample) | ||
| US7169763B2 (en) | Cytochrome P450 3A inhibitors and enhancers | |
| JP2019514990A5 (enExample) | ||
| NO20080244L (no) | Doseringsstyring for prasugrel | |
| TWI842936B (zh) | 包含檸檬苦素類化合物和α-糖苷酶抑制劑的組合產品及其用途 | |
| US20220313708A1 (en) | Combination product containing limonoid compound and sglt-2 inhibitor | |
| JP2016537364A5 (enExample) | ||
| US20080262072A1 (en) | Compositions And Kits Comprising A Melatonin Component And A Flavanol Component |